ACUT Accustem Sciences Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Accustem Sciences Inc. reported revenue of $98.4K, net income of −$253K and diluted EPS of −$0.02; for the fiscal year ended December 2025 revenue was n/a.
ACUT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$1.76M, net income −$1.76M (margin n/a), EPS −$0.12
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$1.51M, net income −$1.51M (margin n/a), EPS −$0.13
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$2.05M, net income −$2.05M (margin n/a), EPS −$0.18
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$3.75M, net income −$3.75M (margin n/a), EPS −$0.34
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$671K, net income −$671K (margin n/a), EPS n/a
ACUT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $98.4K, net income −$253K, EPS −$0.02
- Quarter ended Mar 31, 2026: revenue n/a, net income −$486K, EPS −$0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$514K, EPS −$0.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$400K, EPS −$0.02
- Quarter ended Jun 30, 2025: revenue n/a, net income −$401K, EPS −$0.02
- Quarter ended Mar 31, 2025: revenue n/a, net income −$440K, EPS −$0.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$372K, EPS −$0.03
- Quarter ended Sep 30, 2024: revenue n/a, net income −$328K, EPS −$0.03
- Quarter ended Jun 30, 2024: revenue n/a, net income −$278K, EPS −$0.02
- Quarter ended Mar 31, 2024: revenue n/a, net income −$527K, EPS −$0.05
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$246K, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$599K, EPS −$0.05
- Quarter ended Jun 30, 2023: revenue n/a, net income −$373K, EPS −$0.03
- Quarter ended Mar 31, 2023: revenue n/a, net income −$833K, EPS −$0.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$979K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$899K, EPS −$0.08
- Quarter ended Jun 30, 2022: revenue n/a, net income −$1.08M, EPS −$0.10
- Quarter ended Mar 31, 2022: revenue n/a, net income −$791K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$543K, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$62.7K, EPS n/a
ACUT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$850K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$664K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.62M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.81M, share buybacks n/a
ACUT balance sheet
- Jun 30, 2026: cash n/a, total assets $1.61M, total liabilities $5.72M, shareholders' equity −$4.12M
- Mar 31, 2026: cash n/a, total assets $1.55M, total liabilities $5.42M, shareholders' equity −$3.87M
- Dec 31, 2025: cash n/a, total assets $1.55M, total liabilities $4.95M, shareholders' equity −$3.40M
- Sep 30, 2025: cash n/a, total assets $1.57M, total liabilities $4.48M, shareholders' equity −$2.91M
- Jun 30, 2025: cash n/a, total assets $1.61M, total liabilities $4.15M, shareholders' equity −$2.53M
- Mar 31, 2025: cash n/a, total assets $1.55M, total liabilities $3.71M, shareholders' equity −$2.16M
- Dec 31, 2024: cash n/a, total assets $50.9K, total liabilities $3.36M, shareholders' equity −$3.31M
- Sep 30, 2024: cash n/a, total assets $104K, total liabilities $3.30M, shareholders' equity −$3.19M
Is ACUT profitable?
No. Accustem Sciences Inc. lost $1.65M over the last four quarters.
What is ACUT's EPS?
Diluted earnings per share over the last four quarters were −$0.12; −$0.02 in the latest quarter.